news paper icon

Analyzed News

Merck KGaA lung cancer drug is 3rd on U.S. watchdog's priority lane

Merck KGaA's prospective lung cancer treatment tepotinib became the third drug against a rare and aggressive subtype of the disease that won U.S. Food and Drug Administration's breakthrough therapy designation. [Source]

Publication Date:

Origin: reuters.com

Category: companyNews

Topics: cancer, merck, drug, lung, tepotinib

Source Link: http://feeds.reuters.com/~r/reuters/companyNews/~3/COoBN37zuTo/merck-kgaa-lung-cancer-drug-is-3rd-on-u-s-watchdogs-priority-lane-idUSL5N2621II

Related Articles